P. Bhar

TL;DR: The improved therapeutic index and elimination of corticosteroid premedication required for solvent-based taxanes make the novel albumin-bound paclitaxel ABI-007 an important advance in the treatment of MBC.

TL;DR: The administration of nab-PC as first-line therapy in patients with advanced NSCLC was efficacious and resulted in a significantly improved ORR versus sb-PC, achieving the primary end point.

TL;DR: This phase II study examined the antitumor activity and safety of weekly and every 3 week nab-paclitaxel compared with docetaxel as first-line treatment in patients with MBC and demonstrated superior efficacy and safety.

TL;DR: Data suggest that 150 mg/m(2) qw 3/4 may represent the most clinically efficacious nab-paclitaxel dosing regimen for patients with no previous chemotherapy for MBC, and a phase III trial confirming these results would be necessary and prudent before widespread adoption of the 150 mg/(2) dose in clinical practice.

TL;DR: Nab-Paclitaxel plus carboplatin is an effective therapy for advanced NSCLC and in patients with squamous cell carcinoma, the q3w schedule significantly increased PFS by 3 months (p = 0.014) and OS by >2 months (no difference in RR) compared with the weekly schedule.